Revisiting methylprednisolone aceponate: efficacy, safety and current positioning

Area of Science:

• Dermatology
• Pharmacology

Background:

• Topical corticosteroids are crucial for managing inflammatory skin diseases.
• Optimizing efficacy while minimizing adverse effects of corticosteroids is a key clinical challenge.
• Methylprednisolone aceponate (MPA) is a non-halogenated, fourth-generation corticosteroid designed for enhanced local activity and reduced systemic exposure.

Purpose of the Study:

• To review the pharmacology, clinical efficacy, and safety of Methylprednisolone aceponate (MPA).

Main Methods:

• A comprehensive literature search was conducted using PubMed, covering studies from 1990 to 2025.
• The search focused on identifying relevant studies concerning MPA in the treatment of various inflammatory dermatoses.

Main Results:

• MPA's unique di-esterified structure and 6α-methyl modification confer potent anti-inflammatory properties and low atrophogenic potential.
• Activation within the skin yields a highly active metabolite, while rapid systemic inactivation minimizes absorption. MPA demonstrates rapid pruritus relief and high clearance rates in eczematous conditions.
• Once-daily application is often sufficient, improving patient adherence. MPA's availability in diverse formulations allows for customized treatment based on lesion type and body site.
• Long-term MPA use is associated with a low incidence of skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and rare allergic sensitization.

Conclusions:

• Methylprednisolone aceponate (MPA) presents a highly effective and well-tolerated therapeutic option.
• It is suitable for both acute and maintenance phases of managing inflammatory skin diseases.